The pharmacodynamics of tinzaparin in healthy volunteers

J. Cambus,S. Saivin,J. Heilmann,H. Caplain,B. Boneu,G. Houin
DOI: https://doi.org/10.1046/j.0007-1048.2001.03306.x
2002-03-01
British Journal of Haematology
Abstract:Summary. We report the pharmacodynamic properties of tinzaparin (175 U/kg antifactor Xa) given as a single daily administration for 5 consecutive days to 14 healthy volunteers as a known safe, effective treatment of deep vein thrombosis and pulmonary embolism. The Cmax for antifactor Xa (0·87 ± 0·15 U/ml) was associated with a 2·4 ± 0·5‐fold prolongation of the activated partial thromboplastin time (APTT) and a high antithrombin activity (0·38 ± 0·1 U/ml). The Cmax value of antifactor Xa was 1·5‐ and twofold lower than those generated by similar doses of nadroparin and enoxaparin respectively. The clearance of antifactor Xa activity (1·29 ± 0·2 l/h) was 1·5‐ and twofold greater than those reported for nadroparin and enoxaparin respectively. These results indicated that the antithrombotic and prohaemorrhagic effects of a low molecular weight heparin were independent from the absolute levels of antifactor Xa activities and from the prolongation of the APTT.
What problem does this paper attempt to address?